RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Gilead Sciences Inc.

A collection of news and information related to Gilead Sciences Inc. published by this site and its partners.

Top Gilead Sciences Inc. Articles

Displaying items 1-11
  • InterMune drug may offer big upside to Roche if aimed at liver

    (Reuters) - Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its...
  • Michelle Quinn: Getting more workforce data out of Silicon Valley firms

    Last month, as I mentioned in a previous column, the San Jose Mercury News sent a letter to major Silicon Valley firms asking for information about their companies' work force demographics. And in that previous column, I said I'd update you on how...
  • 'Plantibodies' drugs advance as big pharma stands aside

    LOS ANGELES (Reuters) - Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with the biggest pharmaceutical companies. The leading...
  • UK cost body backs pricey Gilead hepatitis pill for some patients

    LONDON (Reuters) - Gilead Sciences' expensive new hepatitis C pill has been endorsed for use in certain patients by Britain's healthcare cost-effectiveness watchdog, after the U.S. firm provided more information. The National Institute for Health and...
  • New health apps, games reward patients who take their meds

    SAN FRANCISCO (Reuters) - A group of ex-gaming industry executives say they can use their design chops to solve a major health challenge: Sick patients neglecting to take their medication and costing employers and insurance providers billions of dollars....
  • Gilead says panel rejects Roche's claims on hepatitis C drug

    (Reuters) - Gilead Sciences Inc said an arbitration panel rejected Roche Holding AG's patent infringement claims related to Gilead's hepatitis C drug, Sovaldi. Gilead's shares rose as much as 3 percent in early trading. "While this outcome was widely...
  • Achillion's hepatitis C drug shows promise in trial

    (Reuters) - Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending its shares up 18 percent. The mid-stage trial tested Achillion's...
  • Healthcare: A remedy for long-term investors

    CHICAGO (Reuters) - (The opinions expressed here are those of the author, a columnist for Reuters.) For healthcare, gray is the new black. The fastest-growing segment of the global population is aged 60 and over, according to the United Nations...
  • U.S. senators ask Gilead Sciences to explain high cost of hepatitis C drug

    Two U.S. senators asked Gilead Sciences Inc. to produce documents explaining why its new hepatitis C drug is priced at $84,000 per treatment course, raising renewed concerns over the high costs to taxpayers. In a letter sent Friday, Ron Wyden (D-Ore.)...
  • Health Insurers Propose Rate Increases For 2015 Coverage

    Insurance companies selling health plans next fall for coverage in 2015 are asking state regulators to approve prices that reflect medical-cost inflation, and, in some cases, federal mandates, and expensive drugs to treat Hepatitis C. Anthem Blue Cross...
  • HIV: we can and must get to zero [Commentary]

    HIV: we can and must get to zero [Commentary]
    The havoc that HIV can wreak on a family and a community can be devastating. Over the past three decades, we have watched helplessly as friends and family members died from HIV-related illnesses. Each one lived life brimming with hope and energy, prepared...